10-Q 1 lca10q.htm LCA-VISION INC. FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

(Mark One)

[ X ]    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF

            THE SECURITIES EXCHANGE ACT OF 1934.



            For the quarterly period ended March 31, 2002.



[    ]    TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF

           THE SECURITIES EXCHANGE ACT.



            For the transition period from __________ to __________



            Commission file number 0-27610





LCA-Vision Inc.

(Exact name of registrant as specified in its charter)





              Delaware

(State or other jurisdiction of

incorporation or organization)

         11-2882328

(IRS Employer

Identification No.)





7840 Montgomery Road, Cincinnati, Ohio 45236

(Address of principal executive offices)



(513) 792-9292

(Registrant's telephone number, including area code)



Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.



Yes    X               No



Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: April 30, 2002 shares as of 42,964,762.



LCA-Vision Inc.

INDEX







Facing Sheet 1
Index 2
Part I. Financial Information
Item 1.  Financial Statements
Condensed Consolidated Balance Sheets as of March 31, 2002

and December 31, 2001

3
Condensed Consolidated Statements of Income for the Three

Months Ended March 31, 2002 and 2001

4
Condensed Consolidated Statements of Cash Flows for the Three Months Ended

March 31, 2002 and 2001

5
Notes to Condensed Consolidated Financial Statements 6
Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations 8
Item 3.  Quantitative and Qualitative Disclosures About Market Risk 10
Part II. Other Information 11
Item 1.  Legal Proceedings
Item 2.  Changes in Securities and Use of Proceeds
Item 3.  Defaults Upon Senior Securities
Item 4.  Submission of Matters to a Vote of Security Holders
Item 5.  Other Information
Item 6.  Exhibits and Reports on Form 8-K 11
Signatures 12



Condensed Consolidated Balance Sheet
(Dollars in thousands except per share data)
Assets March 31, 2002 (1) December 31, 2001
Current Assets
   Cash and cash equivalents $ 16,708 $ 16,609
   Accounts receivable, net 1,115 517
   Receivable from vendors 494 234
   Prepaid expenses, inventory and other                  1,342                     1,959
Total current assets 19,659 19,319
Property and Equipment 36,713 36,411
Accumulated depreciation and amortization               (15,210)                  (13,753)
Property and equipment, net 21,503 22,658
Goodwill, net 275 275
Investment in unconsolidated businesses 374 290
Other assets, net                     721                         646
Total assets $ 42,532

=============

$ 43,188

=============

Liabilities and Shareholders' Investment
Current liabilities
   Accounts payable $ 2,874 $ 2,645
   Accrued liabilities and other 2,525 2,270
   Debt maturing in one year                       22                         26
Total current liabilities 5,421 4,941
Long-term debt - 4
Minority equity interest 109 41
Shareholders' investment
   Preferred stock
   Common stock ($0.001 par value; 52,338,554 and 52,248,554 shares and
       42,869,762 and 46,045,525 shares issued and outstanding, respectively) 52 52
   Contributed capital 91,201 91,080
   Warrants 2,105 2,105
   Notes receivable from shareholders (1,500) (1,488)
   Common stock in treasury, at cost (9,468,792 shares and 6,203,029 shares) (15,473) (13,013)
   Accumulated deficit (39,361) (40,512)
   Accumulated other comprehensive loss                     (22)                        (22)
Total shareholders' investment                 37,002                  38,202
Total liabilities and shareholders' investment $ 42,532

=============

$ 43,188

=============

(1) Unaudited
The notes to the Condensed Consolidated Financial Statements are an integral part of this statement.



LCA-Vision Inc.
Condensed Consolidated Statements of Income
(Dollars in thousands except per share data)
Three months ended March 31,
2002 (1) 2001 (1)
Revenues
   Laser refractive surgery $ 18,763 $ 22,445
   Other                          45                          45
Total revenues 18,808 22,490
Operating costs and expenses
   Medical professional and license fees 3,778 4,497
   Direct costs of services 7,514 9,301
   General and administrative expenses 2,162 2,175
   Marketing and advertising 3,104 3,411
   Depreciation 1,458 1,386
   Special charge reversal                         (174)                               0
Operating income 966 1,720
Equity in earnings from unconsolidated businesses 117 77
Minority equity interest (67) (4)
Interest (expense) (2) (4)
Interest income 137 301
Other income                                -                                 5
Income before taxes on income 1,151 2,095
Income tax expense                               -                              796
Net income $ 1,151

==============

$ 1,299

===============

Income per common share
   Basic $ 0.03 $ 0.03
   Diluted $ 0.03 $ 0.03
Weighted average shares outstanding
   Basic 43,828 47,045
   Diluted 43,859 47,607
(1) Unaudited
The notes to the Condensed Consolidated Financial Statements are an integral part of this statement.







LCA-Vision Inc.
Condensed Consolidated Statements of Cash Flow
(Dollars in thousands except per share data)

Three Months Ended

March 31,

2002 (1) 2001 (1)
Cash flow from operating activities:
Net income $ 1,151 $ 1,299
Adjustments to reconcile net income to net cash provided by operating activities
   Depreciation 1,458 1,386
   Warrant amortization 175 175
   Deferred income taxes - 796
   Equity in earnings of unconsolidated affiliates (117) (77)
   Special charge reversal (174)
   Changes in working capital:
     Accounts receivable (598) 920
     Receivable from vendor (260) 1,568
     Prepaid expenses, inventory and other 617 (165)
     Accounts payable 229 (3,978)
     Accrued liabilities and other              427              795
Net cash provided by operations 2,908 2,719
Cash flow from investing activities:
   Purchase of property and equipment (302) (727)
   Purchase of short-term investments - (4,378)
   Maturity of short-term investments - 8,626
   Loans to shareholders (12) (421)
   Other, net             (181)             (228)
Net cash used in investing activities (495) 2,872
Cash flows from financing activities:
   Principal payments of long-term notes, debt and capital lease obligations (8) (97)
   Shares repurchased for treasury stock (2,460) (1,066)
   Exercise of stock options 121 53
   Distribution of minority equity investees                33                    -
Net cash used by financing activities (2,314) (1,110)
Increase in cash and cash equivalents 99 4,481
Cash and cash equivalents at beginning of period         16,609          19,692
Cash and cash equivalents at end of period $ 16,708

=========

$ 24,173

========

(1) Unaudited
The notes to the Consolidated Condensed Financial Statements are an integral part of this statement.



LCA-Vision Inc.

Notes to Condensed Consolidated Financial Statements

for the Three Months Ended March 31, 2002 and 2001



1. Summary of Significant Accounting Policies



This filing includes condensed consolidated Balance Sheets as of December 31, 2001 and March 31, 2002; condensed consolidated Statements of Income for the three months ended March 31, 2002 and 2001; and condensed consolidated Statements of Cash Flows for the three months ended March 31, 2002 and 2001. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim period reported. We suggest that these financial statements be read together with the financial statements and notes included in our annual report in Form 10-K.



Business



We are a leading developer and operator of free-standing laser refractive surgery centers. Our laser refractive surgery centers provide the staff, facilities, equipment and support services for performing laser vision correction that employ state-of-the-art laser technologies to correct nearsightedness, farsightedness and astigmatism. The Company currently utilizes two primary excimer lasers: the Bausch & Lomb Technolas 217 and the VISX Star S2 laser. Substantially all of the revenues from our laser vision correction procedures are derived from our North American Centers.



Operating costs and expenses consist of:

- Medical professional and license fees, including per-procedure fees for the ophthalmologist performing laser vision correction and the license fee of $110 per procedure paid to VISX and Bausch & Lomb,

- Direct costs of services, including center rent and utilities, equipment lease and maintenance costs, surgical supplies, center staff expense, costs related to other revenue, and all other costs associated with providing services in our centers,

- General and administrative associated with corporate overhead costs,

- Marketing and advertising costs, and

- Depreciation and amortization of equipment and intangible assets recorded in the balance sheet.



Consolidation Policy



We use two different methods to report our investments in our subsidiaries and other companies: consolidation and the equity method.



Consolidation

We use consolidation when we own a majority of the voting stock of the subsidiary. This means the accounts of our subsidiaries are combined with our accounts. We eliminate intercompany balances and transactions when we consolidate these accounts. Our condensed consolidated financial statements include the accounts of:

- LCA-Vision Inc.,

- LCA-Vision (Canada) Inc. and Subsidiaries, and

- The Baltimore Laser Sight Center, Ltd



Equity Method

We use the equity method to report investments in businesses where we hold 20% to 50% voting interest, giving us the ability to exercise significant influence, but not control, over operating and financial policies. Under the equity method we report:

- our interest in the entity as an investment in our Condensed Consolidated Balance Sheets, and

- our percentage share of the earnings (losses) in our Condensed Consolidated Statements of Operations.



We own 43% of Silmalaseri Oy and 50% of both Cole LCA Vision LLC and Eyemed LCA Vision LLC and report our investments under the equity method.



Goodwill and Other Intangible Assets



Goodwill is the excess of the acquisition cost of the businesses over the fair value of the identifiable net assets acquired. Through December 31, 2001, we amortized goodwill using the straight-line method over the estimated useful life. The Company adopted Financial Accounting Standards (SFAS) No. 142, "Goodwill and Other Intangible Assets" effective January 1, 2002. SFAS 142 discontinued the amortization of goodwill and requires companies to perform annual impairment test of goodwill. Application of the non-amortization provisions of the SFAS No. 142 resulted in a decrease in annual operating expenses of $76,000. During January 2002, the Company completed the first of the required impairment tests of goodwill as of January 1, 2002, which indicated that the Company currently has no goodwill impairment.



Use of Estimates



Management makes estimates and assumptions when preparing financial statements under generally accepted accounting principles. These estimates and assumptions affect various matters including:

- our reported amounts of assets and liabilities in our Condensed Consolidated Balance Sheets at the dates of the financial statements,

- our disclosure of contingent liabilities at the dates of the financial statements, and

- our reported amounts of revenues and expenses in our Condensed Consolidated Statements of Income during the reporting periods.



Actual amounts could differ from those estimates.



Per Share Data



Basic per share data is income applicable to common shareholders divided by the weighted average common shares outstanding. Diluted per share data is income applicable to common shareholders divided by the weighted average common shares outstanding plus the potential issuance of common shares if stock options or warrants were exercised.



Following is a reconciliation of basic and diluted earnings per share for the three months ended March 31, 2002 and 2001 (in thousands, except per share amounts):



Three Months Ended
March 31,
2002 2001
Basic earnings per share
Net income $1,151 $1,299
Weighted average shares outstanding 43,828 47,045
Basic earnings per share $0.03 $0.03
Diluted earnings per share
Net income $1,151 $1,299
Weighted average shares outstanding 43,828 47,045
Effect of dilutive securities
   Stock options 31 539
   Warrants -- 23
Weighted average common shares and potential dilutive shares 43,859 47,607
Diluted earnings per share $0.03 $0.03


Special Charges

During the third quarter of 2001, management implemented a restructuring plan to close unprofitable locations and to reduce operating expenses. The cost of the plan is $1,375,000 which is comprised of a $535,000 restructuring charge and an $840,000 asset impairment charge for leasehold improvements, equipment and goodwill associated with the locations to be closed. The restructuring charges included $384,000 in lease termination costs and $151,000 in severance payments for 71 employees.



During the first quarter of 2002, $88,000 was expended to buyout the remainder of a facility lease. With the restructuring plan fully implemented, $174,000 remaining restructuring reserve was reversed in the first quarter.



Shareholders' Investment



Common Stock

During the three months ended March 31, 2002, 90,000 shares of common stock were issued as a result of exercised stock options. The average exercise price was $1.36 per share.



Segment Information



We operate in one segment - laser refractive surgery.



Commitments and Contingencies



None.



Item 2.  Management's Discussion and Analysis of Financial Condition Results of Operations.



This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors. For a discussion of important factors that could affect our results, refer to the Overview and financial statement line item discussions set forth in Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A").



"MD&A" is an analysis of our operating results for the three months ended March 31, 2002 and 2001 and our financial condition as of March 31, 2002. It explains why our revenues and costs changed, our overall financial condition, and other matters.



Results of Operations - Revenues



Laser refractive surgery



Laser refractive surgery revenue generally includes three components: facility fee, royalty fee, and medical professional fees. Certain states prohibit us from practicing medicine, employing physicians to practice medicine on our behalf or employing optometrists to render optometry services on our behalf. Revenues and direct costs from centers in such states do not include the medical professionals fee component. The contribution from laser refractive surgery procedures for the three months ended March 31, 2002 and 2001 were (dollars in thousands):



Three Months Ended
March 31,
2002 2001
Revenue $18,763 $22,445
Less:
   Medical professional and license fees 3,778 4,497
Contribution $14,985 $17,948


The following table illustrates the growth of laser vision correction procedures performed at our centers.



2002 2001
Q1 17,594 25,061
Q2 22,940
Q3 13,347
Q4 10,684
Year 72,032


Medical professional and license fees

Medical professional expenses decreased by $381,000 from the first quarter of 2001 due to lower procedure revenues. License fees were lower from first quarter 2001 by $351,000 as a result of lower procedure volume.



Direct costs of services

Direct costs of services include the salary component of physician compensation, staffing, equipment, medical supplies, and facility costs to operate laser vision correction centers. These direct costs decreased in the first quarter of 2002 by $1,787,000 compared to the first quarter of 2001, largely because of a decrease in salaries and fringe benefits as a result of cost reduction efforts in prior year and a decrease in laser rent due to purchase of lasers in 2001. Medical supplies decreased by $228,000 in the first quarter of 2002 from the first quarter of 2001 due to lower procedure volume. Exclusive of medical supplies, the average direct cost per center per month increased to $67,100 in the first quarter of 2002 from $65,600 in the fourth quarter of 2001. This increase is primarily due to increases in insurance expense and financing fees resulting from higher volume.



General and administrative

General and administrative expenses decreased by $4,000 in the first quarter of 2002 from the first quarter of 2001. Overall, most expenses compared to 2001 first quarter had decreased, in particular salaries and travel. This was offset by increases in insurance and state and local taxes.



Marketing and advertising expenses

Marketing and advertising expenses decreased by $307,000 in the first quarter of 2002 from the first quarter of 2001. Compared to the fourth quarter of 2001, marketing and advertising expenditures decreased by $7,000.



Depreciation and amortization

Depreciation and amortization expense increased by $73,000 in the first quarter of 2002 from the first quarter of 2001 primarily by the result of purchase of lasers and other equipment that had been leased in the past.



Non-operating income and expenses

Equity earnings in unconsolidated businesses increased by $40,000 in the first three months of 2002 as compared with the first three months of 2001. A growth in the managed care business generated the increase in equity earnings.



Income Taxes

The Company utilized federal and state net operating loss carryforwards in the first quarter of 2002. Therefore, no income tax expense was recorded for the quarter.



Special Charges

During the third quarter of 2001, management implemented a restructuring plan to close unprofitable locations and to reduce operating expenses. The cost of the plan is $1,375,000 which is comprised of a $535,000 restructuring charge and an $840,000 asset impairment charge for leasehold improvements, equipment and goodwill associated with the locations to be closed. The restructuring charges included $384,000 in lease termination costs and $151,000 in severance payments for 71 employees.



During the first quarter of 2002, $88,000 was expended to buy out the remainder of a facility lease. With the restructuring plan fully implemented, $174,000 remaining restructuring reserve was reversed in the first quarter.



Liquidity and Capital Resources

Net cash provided by operating activities in the first three months of 2002 was $2,908,000 which, when combined with beginning of year cash and short-term investment balances, was used to purchase property and equipment to fund the Company's treasury stock purchases.



As of March 31, 2002, we have cash and cash equivalents of $16,708,000.



During the second quarter of 2000, the directors initiated a program to encourage additional direct stock ownership by senior management of the company. The Company offered loans to nine key managers and directors for the purpose of purchasing shares in the open market. Each loan is a personal obligation of the borrower, and is evidenced by a promissory note. The interest rate on the notes is prime less one and one-half percent. The notes have a maximum term of three years, and contain provisions for early repayment. A total of $1,500,000 has been loaned under this program.



As of March 31, 2002 we maintained a $10,000,000 revolving credit facility with The Provident Bank. In addition to the $10,000,000 of unused credit under this facility, the Company has a $10,000,000 line of credit for the purpose of funding acquisitions which is subject to the full and absolute discretion of Provident Bank. Both of these credit arrangements expire June 30, 2002. It is our intent to renew this credit facility for another 12 months on comparable terms.



Factors That May Affect Future Results and Market Price of Stock

For a detailed discussion that may affect future results, please refer to the Company's last 10-K. No material new risks have developed since the filing of these reports.



Item 3. Quantitative and Qualitative Disclosure About Market Risk



The carrying values of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short maturity of these instruments.



We have historically had very low exposure to changes in foreign currency exchange rates, and as such, have not used derivative financial instruments to manage foreign currency fluctuation risk.



Part II.  Other Information
Item 1  Legal Proceedings
                 None
Item 2.  Changes in Securities and Use of Proceeds.
                 None
Item 3.  Defaults upon Senior Securities.
                 None
Item 4.  Submission of Matters to a Vote of Security Holders
                 None
Item 5.  Other Information.
                 None
Item 6.  Exhibits and Reports on Form 8-K.
          (a)  Exhibits
                None
(b) Reports on Form 8-K
1)  Form 8-K dated March 18, 2002, containing a press release announcing documented two-year clinical outcomes at the Company's wholly owned LasikPlus centers using the Bausch & Lomb Technolas 217 laser.
2)  Form 8-K dated April 4, 2002, containing a press release reporting that 17,954 procedures were performed for the three months ended March 31, 2002, compared with 10,684 procedures in the fourth quarter of 2001.
3)  Form 8-K dated April 9, 2002 containing a press release announcing the 10th anniversary of its entry into the fast-growing eyecare sector.






Signatures



In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereto duly authorized.



LCA-VISION INC.





Date: 5/8/02 /s/ Stephen N. Joffe    
Stephen N. Joffe
Chairman and CEO
Date: 5/8/02 /s/ Alan Buckey            
Alan Buckey
Chief Financial Officer